BIOCHEMISTRY • NUCLEOTIDES DNA/RNA & INFORMATION FLOW

DNA Repair Mechanisms

How cells detect and correct the tens of thousands of DNA lesions that arise every day in the human genome.

Historical Context & Motivation

The discovery that DNA is not an inert, immutable molecule but rather a structure under constant assault from both endogenous and exogenous agents fundamentally reshaped our understanding of molecular biology. Estimates suggest that each human cell sustains on the order of 10,000 to 100,000 DNA lesions per day, arising from hydrolysis, oxidation, alkylation, and replication errors. Without robust repair systems, genomes would rapidly degrade, leading to mutagenesis, cell death, and organismal lethality. Early observations of photoreactivation in bacteria exposed to ultraviolet (UV) light hinted that cells possess enzymatic machinery dedicated to restoring DNA integrity. Over the subsequent decades, a rich tapestry of repair pathways was uncovered, each tailored to specific classes of damage and operating through distinct biochemical strategies.

1949
Photoreactivation Discovered
Albert Kelner observed that UV-irradiated bacteria recovered more efficiently when exposed to visible light, revealing the first enzymatic DNA repair process—photolyase-mediated repair of pyrimidine dimers.
1964
Excision Repair Identified
Richard Setlow, along with Philip Hanawalt and David Pettijohn, demonstrated that UV-damaged DNA could be repaired by excising damaged nucleotides and resynthesizing the correct sequence, establishing the concept of nucleotide excision repair (NER).
1976
Mismatch Repair Elucidated
Miroslav Radman proposed the mismatch repair (MMR) system in E. coli, showing that the methyl-directed MutHLS pathway corrects replication errors by distinguishing newly synthesized from template strands.
1994
BRCA Genes and Double-Strand Break Repair
The cloning of BRCA1 linked hereditary breast cancer to defects in homologous recombination (HR) repair of double-strand breaks, forging a direct connection between DNA repair deficiency and cancer predisposition.
2015
Nobel Prize in Chemistry
Tomas Lindahl, Paul Modrich, and Aziz Sancar were awarded the Nobel Prize for their mechanistic studies of base excision repair, mismatch repair, and nucleotide excision repair, respectively, cementing DNA repair as a central pillar of biochemistry.

These milestones collectively frame the central question that DNA repair biology seeks to answer: how do cells detect, identify, and faithfully restore damaged or incorrectly paired nucleotides to maintain genomic stability? Understanding these pathways is not merely an academic exercise—deficiencies in DNA repair underlie numerous cancers, aging phenotypes, and neurological diseases, and they serve as therapeutic targets in modern oncology.

Core Principles of DNA Repair

Despite the diversity of DNA repair pathways, several unifying principles govern how cells maintain genomic integrity. These core ideas provide the conceptual framework for understanding each specific mechanism in subsequent sections. The fidelity of the repair process itself is paramount, because an imprecise fix can be as mutagenic as the original lesion, or worse—it can generate chromosomal rearrangements that drive malignant transformation.

1

Damage Recognition

Repair enzymes must discriminate between normal bases and lesions. Recognition typically relies on detecting distortions in the double helix, abnormal base chemistry, or mismatched base pairs. Specificity is achieved through shape complementarity, thermodynamic probing (base flipping), and protein–DNA contacts.
2

Strand Discrimination

In pathways like mismatch repair, the cell must determine which strand contains the error. In E. coli, hemimethylation of GATC sites marks the template strand; in eukaryotes, strand discontinuities (Okazaki fragment nicks) serve as strand-discrimination signals on the nascent strand.
3

Excise-Resynthesize-Ligate Paradigm

Most repair pathways follow a conserved logic: remove the damaged segment, use the undamaged complementary strand as a template to resynthesize the correct sequence via a DNA polymerase, and then seal the backbone with DNA ligase.
4

Redundancy & Pathway Choice

Cells possess overlapping repair systems, ensuring that a lesion missed by one pathway can be addressed by another. The choice of pathway depends on the type of lesion, cell cycle phase, and chromatin context. Double-strand break repair, for instance, shifts from HR in S/G₂ phase to NHEJ in G₁.
5

Signaling & Coordination

DNA damage activates checkpoint kinases (ATM, ATR, Chk1, Chk2) that arrest the cell cycle, upregulate repair genes, and, if damage is irreparable, trigger apoptosis or senescence. This integrated DNA damage response (DDR) ensures genomic surveillance.
KEY TAKEAWAY
Think of DNA repair like a quality-control assembly line in a factory. The damage sensors are inspectors scanning every product (base pair) for defects. Once a defect is found, the system must determine which part is faulty (strand discrimination), remove the defective component (excision), install a correct replacement from the blueprint (resynthesis using the complementary strand), and weld the seam shut (ligation). Multiple inspection stations exist along the line, so if one inspector misses a defect, the next one catches it—this is the principle of pathway redundancy.

Overview of Major DNA Repair Pathways

The diagram below provides a comprehensive overview of the five major DNA repair pathways and the types of DNA damage each addresses. Each pathway is color-coded and positioned around the central DNA helix, which represents the shared substrate. Arrows indicate the flow from damage type to repair pathway, illustrating the principle that specific lesions are channeled to the pathway best suited for their correction.

The five major DNA repair pathways are arranged around a central DNA double helix. BER (cyan) handles small base modifications; NER (violet) addresses bulky, helix-distorting lesions; MMR (pink) corrects replication errors; HR (emerald) repairs double-strand breaks using a homologous template; and NHEJ (amber) directly ligates broken ends. Key enzymes are shown in monospace within each box.

As shown in the diagram, the left side of the figure groups pathways that address single-strand damage—BER for chemically altered individual bases, NER for bulky adducts that distort the helix, and MMR for misincorporated bases or small insertion–deletion loops. The right side illustrates the two primary pathways for double-strand break repair: homologous recombination, which requires a sister chromatid as a template and is therefore restricted to S and G₂ phases, and non-homologous end joining, which operates throughout the cell cycle but is inherently error-prone because it does not use a homologous template. The key enzymes listed in each box will be discussed in mechanistic detail in the following sections.

Mechanistic Details of Repair Pathways

Base Excision Repair (BER)

Base excision repair is the primary pathway for correcting small, non-helix-distorting base lesions such as 8-oxoguanine (a product of oxidative damage), uracil arising from cytosine deamination, and 3-methyladenine from alkylation. The pathway initiates when a lesion-specific DNA glycosylase recognizes and flips the damaged base out of the double helix into the enzyme's active site, where it cleaves the N-glycosidic bond between the base and the deoxyribose sugar, generating an apurinic/apyrimidinic (AP) site. AP endonuclease 1 (APE1) then incises the phosphodiester backbone 5ʹ to the AP site, creating a single-strand break with a 3ʹ-hydroxyl and a 5ʹ-deoxyribose phosphate (dRP) residue.

In short-patch BER (the predominant sub-pathway), DNA polymerase β (Pol β) fills the single-nucleotide gap and simultaneously removes the 5ʹ-dRP residue via its lyase activity. DNA ligase III, in complex with XRCC1, then seals the nick. In long-patch BER, Pol δ or Pol ε synthesizes a 2–10 nucleotide flap that is cleaved by flap endonuclease 1 (FEN1), and DNA ligase I seals the remaining nick. The choice between short-patch and long-patch BER depends on the nature of the 5ʹ blocking group and the availability of ATP.

Nucleotide Excision Repair (NER)

Nucleotide excision repair removes bulky, helix-distorting lesions, most notably UV-induced cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts, as well as chemical adducts formed by cisplatin and benzo[a]pyrene. NER operates via two sub-pathways that differ in damage recognition but converge on a shared excision mechanism. Global genome NER (GG-NER) scans the entire genome using the XPC–RAD23B complex as the primary sensor, which detects thermodynamic destabilization of the duplex rather than the lesion itself. Transcription-coupled NER (TC-NER) is triggered when RNA polymerase II stalls at a lesion on the template strand, recruiting CSA and CSB proteins to initiate repair.

Following damage verification by TFIIH (through its XPB and XPD helicase subunits), the damaged strand is incised on both sides of the lesion: XPG makes the 3ʹ incision and ERCC1–XPF makes the 5ʹ incision, excising a 24–32 nucleotide oligomer containing the lesion. Replicative polymerases (Pol δ or Pol ε) fill the gap using the undamaged strand as a template, and DNA ligase I or III completes the repair.

Mismatch Repair (MMR)

Mismatch repair corrects base–base mismatches and small insertion–deletion loops that escape the proofreading activity of replicative polymerases. In eukaryotes, the MutSα heterodimer (MSH2–MSH6) recognizes single-base mismatches and 1–2 nucleotide indels, while MutSβ (MSH2–MSH3) preferentially recognizes larger insertion–deletion loops. Upon mismatch binding, MutSα undergoes an ATP-dependent conformational change and recruits MutLα (MLH1–PMS2), which possesses a latent endonuclease activity activated by PCNA loading and RFC. MutLα incises the discontinuous (newly synthesized) strand, and exonuclease 1 (Exo1) degrades the error-containing segment. Pol δ resynthesizes the correct sequence, and DNA ligase I seals the nick.

🧬 Clinical Relevance
Germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) cause Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC), characterized by microsatellite instability and elevated mutation rates. Tumors with MMR deficiency are, however, often highly responsive to immune checkpoint inhibitors because their high neoantigen burden stimulates anti-tumor immunity.

Double-Strand Break Repair: HR and NHEJ

Double-strand breaks (DSBs) are the most cytotoxic form of DNA damage because both strands of the duplex are severed, eliminating the intact complementary strand that other pathways rely upon as a template. Cells repair DSBs primarily through two competing pathways. Homologous recombination (HR) is a high-fidelity pathway that uses the sister chromatid as a template and is therefore active predominantly during S and G₂ phases. The MRN complex (MRE11–RAD50–NBS1) initiates 5ʹ→3ʹ end resection, generating long 3ʹ single-stranded DNA overhangs. RPA coats the ssDNA to prevent secondary structure formation, and then the mediator protein BRCA2 loads RAD51 recombinase onto the ssDNA, displacing RPA and forming a nucleoprotein filament that invades the homologous duplex. After strand invasion, DNA synthesis extends the invading strand, and the repair is completed through resolution or dissolution of Holliday junction intermediates.

Non-homologous end joining (NHEJ) operates throughout the cell cycle and is the predominant DSB repair pathway in G₁, when no sister chromatid is available. The Ku70/Ku80 heterodimer rapidly binds broken DNA ends, recruits DNA-PKcs (DNA-dependent protein kinase catalytic subunit), and tethers the two ends together. End-processing enzymes such as Artemis trim incompatible overhangs, and the XRCC4–DNA ligase IV–XLF complex ligates the ends. Because NHEJ does not use a homologous template, it is inherently error-prone, often introducing small insertions or deletions at the junction. A more mutagenic alternative pathway, alternative end joining (alt-EJ / MMEJ), uses microhomologies of 5–25 nucleotides flanking the break to align ends before ligation, frequently causing larger deletions.

Damage Types and Pathway Classification

Matching the correct repair pathway to a given lesion is a central concept in understanding DNA repair biology. The table below categorizes common types of DNA damage by their source, chemical nature, and the primary repair pathway responsible for their correction. Note that many lesions can be addressed by more than one pathway, reflecting the redundancy that ensures genomic stability.

Common DNA damage types and their primary repair pathways
Damage TypeSource / AgentChemical NaturePrimary Repair Pathway
8-oxoguanineReactive oxygen species (ROS)Oxidized base, can mispair with ABER (OGG1 glycosylase)
Uracil in DNASpontaneous cytosine deaminationNon-native base; U:G mismatchBER (UNG glycosylase)
Cyclobutane pyrimidine dimerUV-B radiation (254–320 nm)Covalent bond between adjacent pyrimidinesNER (GG-NER or TC-NER)
Benzo[a]pyrene-dG adductTobacco smoke, grilled meatsBulky covalent adduct distorting helixNER (GG-NER)
G:T mismatchReplication error (Pol slippage)Non-Watson-Crick base pairMMR (MutSα)
Insertion/deletion loopPolymerase slippage at repeatsExtra or missing nucleotides in one strandMMR (MutSα or MutSβ)
Double-strand breakIonizing radiation, replication fork collapseBoth strands severedHR (S/G₂) or NHEJ (G₁)
Interstrand crosslinkCisplatin, mitomycin C, nitrogen mustardsCovalent link between complementary strandsFanconi anemia pathway + HR + NER
This step-by-step diagram illustrates short-patch BER. Step 1: A DNA glycosylase (e.g., OGG1) recognizes the damaged base (red circle, 8-oxoguanine). Step 2: The glycosylase cleaves the N-glycosidic bond, creating an AP site (dashed red box). Step 3: APE1 incises the backbone 5ʹ to the AP site. Step 4: Pol β fills the single-nucleotide gap with the correct base (green G). Step 5: DNA ligase III–XRCC1 seals the remaining nick, restoring the intact duplex.

Worked Example: Tracking Mutation Rate in MMR-Deficient Cells

While DNA repair is fundamentally a biochemical process, quantitative reasoning allows us to appreciate the functional significance of each pathway. The following worked example demonstrates how loss of mismatch repair elevates the mutation rate and can be detected experimentally through fluctuation assays or microsatellite instability analysis.

Estimating Mutation Rate Enhancement from MMR Loss
1
Step 1 — Establish Baseline Replication Error RateReplicative DNA polymerases (Pol δ and Pol ε) have an intrinsic error rate of approximately 10⁻⁴ to 10⁻⁵ errors per base pair per replication before proofreading. Their 3ʹ→5ʹ exonuclease proofreading activity reduces this to approximately 10⁻⁷ errors per bp per replication. We use this post-proofreading rate as the substrate for mismatch repair.
Post-proofreading error rate ≈ 10−7 per bp per replication
2
Step 2 — Apply MMR Correction FactorMismatch repair corrects approximately 99% to 99.9% of remaining replication errors. This represents a 100- to 1000-fold improvement in fidelity. Taking the geometric mean, MMR reduces the mutation rate by a factor of roughly 10² to 10³. Therefore, the final per-base mutation rate in wild-type cells with functional MMR is: 10⁻⁷ × 10⁻² to 10⁻³ = 10⁻⁹ to 10⁻¹⁰ per bp per cell division.
Wild-type mutation rate ≈ 10−9 to 10−10 per bp per division
3
Step 3 — Calculate Mutations per Genome per DivisionThe human genome comprises approximately 6.4 × 10⁹ bp. Using the wild-type mutation rate of ~5 × 10⁻¹⁰ per bp per division: mutations per genome = (6.4 × 10⁹ bp) × (5 × 10⁻¹⁰ per bp) ≈ 3.2 mutations per cell division. This is consistent with experimental measurements of ~0.5–5 mutations per division in somatic cells.
≈ 3.2 mutations per genome per division (wild-type)
4
Step 4 — Predict MMR-Deficient Mutation RateIn MMR-deficient cells (e.g., MSH2⁻/⁻ or MLH1⁻/⁻), the post-proofreading error rate of ~10⁻⁷ per bp per division is not further reduced. The mutation rate therefore rises to approximately 10⁻⁷ per bp per division, a 100- to 1000-fold increase over wild-type. In terms of mutations per genome: (6.4 × 10⁹) × (10⁻⁷) ≈ 640 mutations per cell division.
≈ 640 mutations per genome per division (MMR-deficient) — a ~200-fold elevation
5
Step 5 — Interpret the Biological ConsequenceThis dramatic elevation in mutation rate generates microsatellite instability (MSI) because repetitive sequences are particularly vulnerable to polymerase slippage errors that MMR normally corrects. Clinically, MSI-high tumors accumulate frameshift mutations in genes containing coding microsatellites (e.g., BAX, TGFβRII), driving tumorigenesis. This calculation underscores why MMR is essential for maintaining replication fidelity and why its loss is a hallmark of Lynch syndrome-associated cancers.
MMR loss → microsatellite instability → accelerated tumorigenesis

Comparing Repair Pathways: Fidelity, Speed, and Context

Each DNA repair pathway occupies a distinct niche defined by the type of damage it corrects, the fidelity of the repair, its speed of action, and the cell cycle phases in which it operates. The table below provides a side-by-side comparison that highlights the strengths and limitations of each major pathway, enabling students to predict which repair strategy a cell would deploy given a particular lesion and cellular context.

Comparative features of the five major DNA repair pathways
FeatureBERNERMMRHRNHEJ
Lesion typeSmall base modificationsBulky, helix-distorting adductsMismatches, indelsDouble-strand breaksDouble-strand breaks
Patch size1 nt (short) or 2–10 nt (long)24–32 ntUp to ~1 kbVariable (gene conversion tract)0–5 nt processing
FidelityHighHighHighHighLow (error-prone)
SpeedFast (minutes)Moderate (hours)Coupled to replicationSlow (hours)Fast (minutes)
Cell cycleAll phasesAll phases (TC-NER needs transcription)S phase (post-replication)S/G₂ onlyAll phases (predominant in G₁)
Template required?Complementary strandComplementary strandComplementary strandSister chromatidNone
Disease linkMUTYH polyposisXeroderma pigmentosum, Cockayne syndromeLynch syndromeBRCA1/2 breast/ovarian cancerLIG4 syndrome, SCID
KEY TAKEAWAY
The choice between DNA repair pathways mirrors a triage system in an emergency department. Minor injuries (single-base lesions) are handled rapidly in the outpatient clinic (BER). Complex wounds (bulky adducts) require a specialist surgical team (NER). Quality-control audits (mismatches) are part of post-operative review (MMR). Life-threatening trauma (double-strand breaks) gets the most resource-intensive response—ideally precision microsurgery (HR), but when time or resources are limited, emergency field suturing (NHEJ) is used, accepting the risk of scarring.

Connections to Advanced Topics: Synthetic Lethality & Therapy

The study of DNA repair mechanisms has yielded transformative advances in cancer therapy, particularly through the concept of synthetic lethality. Two genes are synthetically lethal when loss of either alone is viable, but simultaneous loss of both is lethal. In the context of DNA repair, tumor cells with a pre-existing deficiency in one repair pathway (e.g., HR due to BRCA1/2 mutation) become critically dependent on a backup pathway (e.g., BER/single-strand break repair involving PARP1). Pharmacological inhibition of this backup pathway with PARP inhibitors (olaparib, niraparib, rucaparib) selectively kills HR-deficient cancer cells while sparing normal cells that have functional HR. This therapeutic strategy, validated in clinical trials for BRCA-mutated breast and ovarian cancers, represents a paradigm shift from cytotoxic chemotherapy toward genotype-targeted therapy.

Undergraduate vs. graduate-level depth in DNA repair topics
ConceptUndergraduate Level (This Lesson)Advanced / Graduate Level
Pathway regulationCell cycle-dependent choice between HR and NHEJCDK-dependent phosphorylation of CtIP, 53BP1/BRCA1 antagonism, chromatin remodeling at DSBs
Checkpoint signalingATM/ATR activate Chk1/Chk2 → cell cycle arrestγH2AX spreading, MDC1 scaffolding, RNF8/RNF168 ubiquitin signaling, liquid–liquid phase separation at damage sites
Translesion synthesisDNA damage tolerance via error-prone polymerases (Pol η, Pol ζ)PCNA monoubiquitination by RAD6/RAD18, polymerase switching mechanisms, template switching vs. TLS
Therapeutic targetingPARP inhibitors exploit HR deficiency (synthetic lethality)ATR inhibitors, DNA-PKcs inhibitors, POLQ inhibitors, radioligand-conjugated DNA damagers
Epigenetic dimensionsMLH1 promoter methylation silences MMR in sporadic cancersHistone modifications (H3K36me3 recruits MutSα), R-loops as sources of replication stress, transcription-replication conflicts

As you advance in your studies, you will encounter increasingly sophisticated regulatory layers governing DNA repair, including post-translational modifications (ubiquitylation, SUMOylation, PARylation), chromatin dynamics, and the interplay between repair pathways and replication fork stability. The foundational knowledge of the five major repair pathways presented in this lesson provides the essential framework upon which these advanced concepts are built.

Practice Problems

PROBLEM 1CONCEPTUAL
A patient with xeroderma pigmentosum (XP) develops severe sunburn and freckling after minimal sun exposure and is at dramatically elevated risk for skin cancer. Which DNA repair pathway is defective in this disease, and why does UV radiation pose a uniquely severe threat to these individuals?
PROBLEM 2BASIC CALCULATION
If the post-proofreading replication error rate is 10⁻⁷ per bp per division, and MMR corrects 99.9% of these errors, calculate: (a) the final mutation rate per bp per division, and (b) the approximate number of new mutations per genome per division in a human cell (genome size ≈ 6.4 × 10⁹ bp).
PROBLEM 3INTERMEDIATE
A researcher finds that a newly characterized DNA glycosylase excises hypoxanthine (the deamination product of adenine) from DNA. Predict the full sequence of enzymatic steps required to complete the repair of this lesion via short-patch BER, naming each enzyme involved and describing its activity.
PROBLEM 4APPLIED
A patient with BRCA2-mutated ovarian cancer is treated with the PARP inhibitor olaparib and shows a dramatic tumor response. Explain the molecular basis of this therapeutic effect using the concept of synthetic lethality. Why would a patient with the same cancer type but wild-type BRCA2 be unlikely to benefit from this drug alone?
PROBLEM 5CRITICAL THINKING
Consider a hypothetical organism in which all five major DNA repair pathways are fully functional, but the organism lacks DNA damage checkpoint signaling (ATM, ATR, Chk1, Chk2 are all absent). Predict how this organism's response to DNA damage would differ from wild-type, even though the repair machinery itself is intact. What types of genomic instability might arise, and why?

DNA Repair Mechanisms — Summary

DNA is constantly damaged by endogenous and exogenous agents, but cells maintain genomic integrity through five major repair pathways. Base excision repair (BER) corrects small, non-helix-distorting lesions (oxidized bases, deaminations) via a glycosylase → APE1 → Pol β → ligase cascade. Nucleotide excision repair (NER) removes bulky, helix-distorting adducts (UV dimers, chemical crosslinks) by excising a 24–32 nucleotide oligomer, with sub-pathways for global genome surveillance (GG-NER) and transcription-coupled repair (TC-NER). Mismatch repair (MMR) corrects replication errors missed by polymerase proofreading, using the MutSα/MutLα system and strand-discrimination signals to ensure the newly synthesized strand is corrected. These three pathways share the excise-resynthesize-ligate paradigm and all rely on the intact complementary strand as a template.

Double-strand breaks, the most dangerous lesions, are repaired by homologous recombination (HR) in S/G₂ phase using the sister chromatid as a template (high fidelity, requiring BRCA1/2 and RAD51) or by non-homologous end joining (NHEJ) throughout the cell cycle (fast but error-prone, using Ku70/80 and DNA ligase IV). The DNA damage response (DDR) coordinates repair with cell cycle checkpoints via ATM/ATR kinases, ensuring repair is completed before replication or division. Deficiencies in these pathways cause cancer predisposition syndromes (xeroderma pigmentosum, Lynch syndrome, BRCA-associated cancers) and are exploited therapeutically through synthetic lethality strategies such as PARP inhibitor treatment of HR-deficient tumors.

Varsity Tutors • Biochemistry • DNA Repair Mechanisms